Astellas Withdrew Its Inflation Reduction Act Lawsuit—Will Other Companies Follow?

Astellas Pharma voluntarily dismissed its lawsuit against the Biden administration earlier this month after its drug Xtandi was not among the initial list of 10 drugs selected for the Inflation Reduction Act’s Drug Price Negotiation Program. While Astellas was the first pharma company to do so, it might not be the last as the legal battle over the IRA has moved to federal court in Ohio with the Department of Justice and U.S. Chamber of Commerce sparring over the law.